Mitra P Maz1, J Michelle Kahlenberg2. 1. Immunology and Division of Rheumatology. 2. Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
PURPOSE OF REVIEW: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multiple manifestations, with a majority of SLE patients having cutaneous involvement. Despite ongoing research, the relationship between SLE and cutaneous lupus erythematosus (CLE) pathogeneses remains unknown. This review will compare advances in understanding the cause and pathogenesis of SLE and CLE. RECENT FINDINGS: Recently, mechanisms by which immune cell populations contribute to the pathogenesis of SLE and CLE have been queried. Studies have pointed to transitional B cells and B-cell activating factor (BAFF) signaling as potential drivers of SLE and CLE, with belimumab clinical data supporting these hypotheses. Ustekinumab trials and an exciting regulatory T cell (Treg) adoptive transfer in an SLE patient with cutaneous disease have suggested a role for T-cell-targeted therapies. The theory that neutrophil extracellular traps may be a source of autoantigens in SLE remains controversial, while neutrophils have been suggested as early drivers of cutaneous disease. Finally, plasmacytoid dendritic cells (pDCs) have been studied as a potential therapeutic target in SLE, and anti-blood DC antigen (anti-BDCA) antibody clinical trials have shown promise in treating cutaneous disease. SUMMARY: Although recent findings have contributed to understanding SLE and CLE pathogenesis, the mechanistic link between these diseases remains an area requiring further research.
PURPOSE OF REVIEW: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multiple manifestations, with a majority of SLE patients having cutaneous involvement. Despite ongoing research, the relationship between SLE and cutaneous lupus erythematosus (CLE) pathogeneses remains unknown. This review will compare advances in understanding the cause and pathogenesis of SLE and CLE. RECENT FINDINGS: Recently, mechanisms by which immune cell populations contribute to the pathogenesis of SLE and CLE have been queried. Studies have pointed to transitional B cells and B-cell activating factor (BAFF) signaling as potential drivers of SLE and CLE, with belimumab clinical data supporting these hypotheses. Ustekinumab trials and an exciting regulatory T cell (Treg) adoptive transfer in an SLE patient with cutaneous disease have suggested a role for T-cell-targeted therapies. The theory that neutrophil extracellular traps may be a source of autoantigens in SLE remains controversial, while neutrophils have been suggested as early drivers of cutaneous disease. Finally, plasmacytoid dendritic cells (pDCs) have been studied as a potential therapeutic target in SLE, and anti-blood DC antigen (anti-BDCA) antibody clinical trials have shown promise in treating cutaneous disease. SUMMARY: Although recent findings have contributed to understanding SLE and CLE pathogenesis, the mechanistic link between these diseases remains an area requiring further research.
Authors: Magdalene Nakou; George Bertsias; Ilias Stagakis; Michael Centola; Ioannis Tassiulas; Maria Hatziapostolou; Iraklis Kritikos; George Goulielmos; Dimitrios T Boumpas; Dimitrios Iliopoulos Journal: PLoS One Date: 2010-10-14 Impact factor: 3.240
Authors: Vanja Sisirak; Dipyaman Ganguly; Kanako L Lewis; Coline Couillault; Lena Tanaka; Silvia Bolland; Vivette D'Agati; Keith B Elkon; Boris Reizis Journal: J Exp Med Date: 2014-09-01 Impact factor: 14.307
Authors: Lisa Abernathy-Close; Stephanie Lazar; Jasmine Stannard; Lam C Tsoi; Sean Eddy; Syed M Rizvi; Christine M Yee; Emily M Myers; Rajaie Namas; Lori Lowe; Tamra J Reed; Fei Wen; Johann E Gudjonsson; J Michelle Kahlenberg; Celine C Berthier Journal: Front Immunol Date: 2021-11-19 Impact factor: 7.561
Authors: Brittany A Martínez; Sneha Shrotri; Kathryn M Kingsmore; Prathyusha Bachali; Amrie C Grammer; Peter E Lipsky Journal: Sci Adv Date: 2022-04-29 Impact factor: 14.957